To further characterize whether these ruthenium complexes affected the BRCA1 protein, we performed ruthenium-BRCA1 interactions in vitro, and utilized the N-terminal BRCA1 RING domain protein (1–304 amino acid residues without mutating BRCA1 that play a vital role in E3 ubiquitin ligase activity) as a representative of all breast cancer cell lines used in this study. This evidence concerns the gene BRCA1 and breast carcinoma.